What can Pharma learn from the Private Equity sector? |
Print this page
Email to a colleague
|
What can Pharma learn from the Private Equity sector?
Adobe PDF Format - 496K
We believe that looking at Pharma through the lens used by the private equity sector yields some valuable insights from which the bravest and most imaginative companies can learn. As an article recently published in the Harvard Business Review points out, the best private equity funds consistently deliver higher returns than the S&P 500 – and they do so because they have developed the strategies and processes needed to obtain a superior performance from the companies in which they invest, not because they engage in manipulative or short-term tactics.
While some of these practices may depend on private ownership, many are relevant to public companies and could make Pharma much stronger. To borrow from the words of one venture capitalist to whom we talked, “Private equity isn’t about changing paradigms. But changing the way in which things are funded and done can end up getting paradigms changed.”
© 2010 PricewaterhouseCoopers. All rights reserved. "PricewaterhouseCoopers" and "PwC" refer to the network of member firms of PricewaterhouseCoopers International Limited (PwCIL). Each member firm is a separate legal entity and does not act as agent of PwCIL or any other member firm. PwCIL does not provide any services to clients. PwCIL is not responsible or liable for the acts or omissions of any of its member firms nor can it control the exercise of their professional judgment or bind them in any way. No member firm is responsible or liable for the acts or omissions of any other member firm nor can it control the exercise of another member firm's professional judgment or bind another member firm or PwCIL in any way.
Bookmark with: